Daily non-political popular news in brief.

Lung cancer-derived EGFR mutants exhibit intrinsic differences in inhibitor sensitivity

A new study sheds light on how some small-molecule tyrosine kinase inhibitors, including two that are currently being used clinically to treat cancer, interact with wild-type and mutated forms of the epidermal growth factor receptor (EGFR).

Read more »

Keywords: lung, cancer-derived, egfr, mutants, exhibit, intrinsic, differences, inhibitor, sensitivity, cancer, derived, mutant, difference

« Previous | Next »

Similar news on "Lung cancer-derived EGFR mutants exhibit intrinsic differences in inhibitor sensitivity":

1. Gene analysis might explain ethnic differences in sensitivity to chemotherapy in lung cancer
   04-23-2007 · UT Southwestern Medical Center
   Analysis of three genetic mechanisms that cause non-small cell lung cancer might explain why East Asians respond better than other ethnic groups to a certain type of chemotherapy, a team led by UT Southwestern Medical Center researchers has found.
   Similar news · Read more »
   
2. New antibody for EGFR causes lung cancer regression
   01-25-2007 · EurekAlert!
   Mutant forms of the protein EGFR are involved in lung cancer development in many individuals, but not all individuals express the same mutant EGFR. A new study shows that both a mouse EGFR-specific antibody (mAb806) and its humanized form (ch806) cause lung tumor regression in two mouse models of lung cancer, leading to the suggestion that ch806 might provide a new approach to treat patients with lung cancer driven by mutant forms of EGFR.
   Similar news · Read more »
   
3. Gene analysis might explain ethnic differences in sensitivity to chemotherapy in lung cancer
   04-23-2007 · EurekAlert!
   Analysis of three genetic mechanisms that cause nonsmall cell lung cancer might explain why East Asians respond better than other ethnic groups to a certain type of chemotherapy, a team led by UT Southwestern Medical Center researchers has found.
   Similar news · Read more »
   
4. Gene variations point to why lung cancer drugs work better in Japanese vs. US patients
   06-02-2007 · EurekAlert!
   Recent clinical trials revealed that Japanese lung cancer patients survived longer and had a higher rate of side effects than US patients taking the same two drugs, paclitaxel and carboplatin. Now a new study by the Southwest Oncology Group uncovers genetic differences that may explain why. The results, embargoed for release 8:30 a.m. ET Saturday, June 2, are being highlighted at the American Society of Clinical Oncology annual meeting.
   Similar news · Read more »
   
5. New protein inhibitor impedes growth of cancerous cells
   02-08-2007 · EurekAlert!
   Researchers have developed a small-molecule inhibitor of a protein that plays key roles in the control of cell division, and they show that the inhibitor can halt the growth of tumors in mice and cancer-derived cells growing in culture.
   Similar news · Read more »
   
6. Substance in tree bark could lead to new lung-cancer treatment
   06-25-2007 · UT Southwestern Medical Center
   Researchers at UT Southwestern Medical Center have determined how a substance derived from the bark of the South American lapacho tree kills certain kinds of cancer cells, findings that also suggest a novel treatment for the most common type of lung cancer.
   Similar news · Read more »
   
7. JCI table of contents: January 25, 2006
   01-25-2007 · EurekAlert!
   This release contains summaries, links to PDFs and contact information for the following newsworthy papers to be published online, January 25, 2006, in the JCI, including: Carbon monoxide protects mice from multiple sclerosis; New antibody for EGFR causes lung cancer regression; Adiponectin helps clear away apoptotic cells; Ha-ras goes it alone in bladder cancer; and How one bacterium causes diarrhea.
   Similar news · Read more »
   
8. Other highlights in the May 2 JNCI
   05-01-2007 · EurekAlert!
   Also in the May 2 JNCI is a follow-up to the Italian Randomized Tamoxifen Trial, a study on treating breast cancer patients with three HER inhibitor drugs, an increase in survival rates for indolent lymphoma patients using a chemotherapy-rituximab combination, and new lung cancer risk prediction models.
   Similar news · Read more »
   
9. DMP1 deletion cooperates with oncogenic K-ras in lung cancer
   10-15-2007 · EurekAlert!
   Scientists have identified the transcription factor DMP1 as a pivotal tumor suppressor for both human and mouse lung cancers, especially in carcinomas that exhibit intact Arf-p53 pathways. The research, published by Cell Press in the October 2007 issue of Cancer Cell, may lead to development of new drug therapies for lung cancer.
   Similar news · Read more »
   
10. Novel EGFR antibody outperforms cetuximab in mouse model of lung cancer
    01-26-2007 · EurekAlert!
    A study conducted at the Dana-Farber Cancer Institute and the Ludwig Center at Dana-Farber/Harvard Medical School now suggests that antibodies binding a particular protein conformation, caused by hyperactivation, might have distinct therapeutic advantages over antibodies, like cetuximab, that bind to wild-type (normal) target proteins.
    Similar news · Read more »